380 related articles for article (PubMed ID: 25482067)
21. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.
Sung KS; Lee YA; Kim ET; Lee SR; Ahn JH; Choi CY
Exp Cell Res; 2011 Apr; 317(7):1060-70. PubMed ID: 21192925
[TBL] [Abstract][Full Text] [Related]
22. Nuclear bodies and compartments: functional roles and cellular signalling in health and disease.
Zimber A; Nguyen QD; Gespach C
Cell Signal; 2004 Oct; 16(10):1085-104. PubMed ID: 15240004
[TBL] [Abstract][Full Text] [Related]
23. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies.
Bernardi R; Pandolfi PP
Nat Rev Mol Cell Biol; 2007 Dec; 8(12):1006-16. PubMed ID: 17928811
[TBL] [Abstract][Full Text] [Related]
24. Unravelling the molecular interplay: SUMOylation, PML nuclear bodies and vascular cell activity in health and disease.
Berkholz J; Karle W
Cell Signal; 2024 Jul; 119():111156. PubMed ID: 38574938
[TBL] [Abstract][Full Text] [Related]
25. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
26. Role of promyelocytic leukemia protein in host antiviral defense.
Geoffroy MC; Chelbi-Alix MK
J Interferon Cytokine Res; 2011 Jan; 31(1):145-58. PubMed ID: 21198351
[TBL] [Abstract][Full Text] [Related]
27. Nucleus accumbens associated 1 is recruited within the promyelocytic leukemia nuclear body through SUMO modification.
Tatemichi Y; Shibazaki M; Yasuhira S; Kasai S; Tada H; Oikawa H; Suzuki Y; Takikawa Y; Masuda T; Maesawa C
Cancer Sci; 2015 Jul; 106(7):848-56. PubMed ID: 25891951
[TBL] [Abstract][Full Text] [Related]
28. The PML-nuclear inclusion of human supraoptic neurons: a new compartment with SUMO-1- and ubiquitin-proteasome-associated domains.
Villagra NT; Navascues J; Casafont I; Val-Bernal JF; Lafarga M; Berciano MT
Neurobiol Dis; 2006 Jan; 21(1):181-93. PubMed ID: 16125395
[TBL] [Abstract][Full Text] [Related]
29. [Post-translational Modifications of PML in Regulating the Functions of Nuclear Bodies --Review].
Ma XF; Tan Y; Li SF; Jin W; Wang KK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1696-1700. PubMed ID: 31607334
[TBL] [Abstract][Full Text] [Related]
30. β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.
Satow R; Shitashige M; Jigami T; Fukami K; Honda K; Kitabayashi I; Yamada T
Gastroenterology; 2012 Mar; 142(3):572-81. PubMed ID: 22155184
[TBL] [Abstract][Full Text] [Related]
31. C-terminal motifs in promyelocytic leukemia protein isoforms critically regulate PML nuclear body formation.
Li C; Peng Q; Wan X; Sun H; Tang J
J Cell Sci; 2017 Oct; 130(20):3496-3506. PubMed ID: 28851805
[TBL] [Abstract][Full Text] [Related]
32. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
[TBL] [Abstract][Full Text] [Related]
33. Three-dimensional organization of promyelocytic leukemia nuclear bodies.
Lang M; Jegou T; Chung I; Richter K; Münch S; Udvarhelyi A; Cremer C; Hemmerich P; Engelhardt J; Hell SW; Rippe K
J Cell Sci; 2010 Feb; 123(Pt 3):392-400. PubMed ID: 20130140
[TBL] [Abstract][Full Text] [Related]
34. Stability of HTLV-2 antisense protein is controlled by PML nuclear bodies in a SUMO-dependent manner.
Dubuisson L; Lormières F; Fochi S; Turpin J; Pasquier A; Douceron E; Oliva A; Bazarbachi A; Lallemand-Breitenbach V; De Thé H; Journo C; Mahieux R
Oncogene; 2018 May; 37(21):2806-2816. PubMed ID: 29507418
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of endogenous RNF4 exacerbates ischaemia-induced cardiomyocyte apoptosis in mice.
Qiu F; Han Y; Shao X; Paulo P; Li W; Zhu M; Tang N; Guo S; Chen Y; Wu H; Zhao D; Liu Y; Chu W
J Cell Mol Med; 2020 Sep; 24(17):9545-9559. PubMed ID: 32722882
[TBL] [Abstract][Full Text] [Related]
36. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
[TBL] [Abstract][Full Text] [Related]
37. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
Jeanne M; Lallemand-Breitenbach V; Ferhi O; Koken M; Le Bras M; Duffort S; Peres L; Berthier C; Soilihi H; Raught B; de Thé H
Cancer Cell; 2010 Jul; 18(1):88-98. PubMed ID: 20609355
[TBL] [Abstract][Full Text] [Related]
38. Death-domain associated protein-6 (DAXX) mediated apoptosis in hantavirus infection is counter-balanced by activation of interferon-stimulated nuclear transcription factors.
Khaiboullina SF; Morzunov SP; Boichuk SV; Palotás A; St Jeor S; Lombardi VC; Rizvanov AA
Virology; 2013 Sep; 443(2):338-48. PubMed ID: 23830076
[TBL] [Abstract][Full Text] [Related]
39. An L2 SUMO interacting motif is important for PML localization and infection of human papillomavirus type 16.
Bund T; Spoden GA; Koynov K; Hellmann N; Boukhallouk F; Arnold P; Hinderberger D; Florin L
Cell Microbiol; 2014 Aug; 16(8):1179-200. PubMed ID: 24444361
[TBL] [Abstract][Full Text] [Related]
40. Body language: the function of PML nuclear bodies in apoptosis regulation.
Hofmann TG; Will H
Cell Death Differ; 2003 Dec; 10(12):1290-9. PubMed ID: 12934066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
